#Germany #Berlin #Drug Safety #SCIRENT #Wilhelm Haverkamp

SCIRENT Welcomes Prof. Dr. Wilhelm Haverkamp as Chief Medical Officer

In a strategic move to bolster its medical and scientific leadership, SCIRENT has announced the appointment of Prof. Dr. Wilhelm Haverkamp as its new Chief Medical Officer (CMO). This decision was made effective immediately, showcasing SCIRENT's commitment to advancing the field of drug safety and clinical research oversight.

Prof. Dr. Haverkamp brings with him over thirty years of extensive experience in both research and clinical practice, particularly in the area of cardiac electrophysiology. His remarkable accolade as an internationally recognized expert positions him to significantly enhance SCIRENT's capabilities in the cardiovascular domain. He will focus on building and expanding structured safety services, including the establishment of Data Safety Monitoring Committees (DSMCs) and Clinical Event Committees (CECs).

"I am delighted to join SCIRENT and look forward to contributing my expertise to further develop innovative and high-quality drug safety services," stated Prof. Haverkamp. His commitment reflects the high priority placed on patient safety and scientific excellence, particularly in the realm of clinical research, which he aims to champion at SCIRENT.

Throughout his distinguished career, Prof. Haverkamp has developed a deep understanding of various cardiovascular conditions, including acquired and inherited arrhythmias, heart failure, cardiomyopathies, and cardiogenetics. His research interests extend across experimental, translational, and clinical studies that delve into disease mechanisms, diagnostics, and therapeutic approaches.

In recent years, his endeavors have also included contributions to artificial intelligence-enhanced cardiac diagnostics, paving the way for advancements in precision cardiology. His expertise is backed by an impressive portfolio of over 420 publications in esteemed cardiovascular journals, reflecting his contributions to both the scientific community and practical medical fields.

Prof. Haverkamp completed his medical education in Münster and continued to specialize in internal medicine and cardiology at the University Hospital Münster, later becoming senior physician and head of electrophysiology until 2002. Since then, he has been associated with the renowned Charité – Universitätsmedizin Berlin, where he holds a professorship in electrophysiology, leading the electrophysiology unit at the Department of Cardiology until 2017. Furthermore, he served as acting head of the department for significant periods, from 2009 to 2014.

His involvement extends beyond academia; he is an active participant in the German Cardiac Society and the European Society of Cardiology, contributing to clinical guidelines, scientific exchange, and educational initiatives. Additionally, Prof. Haverkamp has played pivotal roles as a principal investigator in numerous clinical trials across national and international landscapes, advising pharmaceutical companies and regulatory bodies on matters concerning drug safety and cardiovascular research.

"We are very pleased to welcome such an experienced and internationally respected expert to SCIRENT," commented Prof. Hans-Dirk Düngen, emphasizing that Prof. Haverkamp's profound expertise will augment SCIRENT's medical capabilities and facilitate the expansion of its service offerings. This appointment marks a significant step in SCIRENT’s ongoing commitment to enhancing the quality of clinical research and patient safety.

About SCIRENT

Founded in 2012, SCIRENT brings innovative therapies and medical devices within reach for patients suffering from cardiovascular diseases. Over the past decade, the company has effectively managed complex multi-site studies, demonstrating its capacity through an accomplished team of clinical and regulatory professionals while maintaining a robust network of experienced cardiovascular research sites across Europe and North America. For additional information about SCIRENT, visit www.scirent.com.